Biomea Fusion, Inc. (BMEA)
NASDAQ$2.54
Market Cap
$92.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
265 of 924
Rank in Industry
150 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BMEA Insider Trading Activity
BMEA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $155,961 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Hitchcock Michael J.M. | director | 1 | $100,600 | 0 | $0 | $100,600 |
| Valle Franco | Chief Financial Officer | 1 | $55,361 | 0 | $0 | $55,361 |
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Activity of Biomea Fusion, Inc.
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $155,961 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $8.28M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (director) — $100,600. Valle Franco (Chief Financial Officer) — $55,361.
The last purchase of 10,000 shares for transaction amount of $100,600 was made by Hitchcock Michael J.M. (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Biomea Fusion, Inc.
| 2024-09-30 | Hitchcock Michael J.M. | director | 10,000 0.029% | $10.06 | $100,600 | -56.34% | ||
| 2024-06-11 | Valle Franco | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +27.31% | ||
| 2023-06-01 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.49% | |
| 2023-05-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.29% | |
| 2023-05-12 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.59% | |
| 2023-05-09 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.05% | |
| 2023-05-08 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.35% | |
| 2023-04-20 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.68% | |
| 2023-03-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.45% | |
| 2023-03-30 | Chen Bihua | 400,000 1.2695% | $30.00 | $12M | -47.02% | |||
| 2022-11-14 | Hitchcock Michael J.M. | director | 5,000 0.0169% | $7.93 | $39,650 | +88.58% | ||
| 2022-11-11 | Valle Franco | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.83% | ||
| 2022-08-16 | A2A Pharmaceuticals, Inc. | 30,684 0.1067% | $13.87 | $425,648 | -9.55% | |||
| 2022-07-21 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | ||
| 2022-06-24 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | ||
| 2022-01-14 | Valle Franco | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% | ||
| 2021-09-17 | Stergiopoulos Sotirios | director | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | ||
| 2021-09-17 | A2A Pharmaceuticals, Inc. | 10 percent owner | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | ||
| 2021-08-23 | Erdtmann Rainer M | President & COO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% | ||
| 2021-08-23 | Butler Thomas Andrew | CEO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% |
Total: 27
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Valle Franco | Chief Financial Officer | 42500 0.1173% | $107,950.00 | 3 | 0 | +36.72% |
| Hitchcock Michael J.M. | director | 15000 0.0414% | $38,100.00 | 2 | 0 | +88.58% |
| Stergiopoulos Sotirios | director | 4400000 12.1417% | $11.18M | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 9.8538% | $9.07M | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 9.6582% | $8.89M | 2 | 9 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,786,289 | 136 | 5.55% | $95.3M | |
$49,091,668 | 110 | 13.11% | $83.06M | |
$155,580,641 | 77 | -24.21% | $86.51M | |
$47,282,828 | 47 | -17.38% | $96.94M | |
$7,147,964 | 34 | 24.78% | $96.35M |
BMEA Institutional Investors: Active Positions
| Increased Positions | 63 | +67.02% | 3M | +11.79% |
| Decreased Positions | 37 | -39.36% | 3M | -13.32% |
| New Positions | 34 | New | 2M | New |
| Sold Out Positions | 11 | Sold Out | 194,521 | Sold Out |
| Total Postitions | 120 | +27.66% | 23M | -1.53% |
BMEA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $15,709.00 | 15.1% | 5.44M | +4,278 | +0.08% | 2024-12-31 |
| Cormorant Asset Management, Lp | $10,320.00 | 9.92% | 3.57M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $6,414.00 | 6.17% | 2.22M | -77,297 | -3.37% | 2024-12-31 |
| Baker Bros. Advisors Lp | $4,196.00 | 4.03% | 1.45M | -656,959 | -31.15% | 2024-12-31 |
| Vanguard Group Inc | $4,049.00 | 3.89% | 1.4M | +3,216 | +0.23% | 2024-12-31 |
| Aisling Capital Management Lp | $2,308.00 | 2.22% | 798,757 | 0 | 0% | 2024-12-31 |
| State Street Corp | $1,747.00 | 1.68% | 604,364 | -36,831 | -5.74% | 2024-12-31 |
| Geode Capital Management, Llc | $1,746.00 | 1.68% | 604,147 | +2,668 | +0.44% | 2024-12-31 |
| Two Sigma Investments, Lp | $1,618.00 | 1.56% | 559,930 | +286,049 | +104.44% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,445.00 | 1.39% | 500,000 | -400,000 | -44.44% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.